Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment [MSNBC.com]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: MSNBC.com
RocheFirst-quarter sales came in at 14.7 billion Swiss francs ($18.7 billion), down 5% year-on-year — but up 6% on a constant currency basis.The appreciation of the Swiss franc against most currencies, notably the U.S. dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates, Roche said.The Swiss franc fell 12% against the U.S. dollar in 2025 and is down another 1% so far this year.CEO Thomas Schinecker defended the company's quarterly results, saying it's a "question on how you look at the reporting," and that while the Swiss franc appreciates, sales reported in U.S. dollars increased by 9%."We spend most of our money in the U.S., and we have most our debt in the U.S., we've just recently bought another company in the U.S.," he told Squawk Box Europe."We will continue to invest in the U.S., and we don't see that as a major issue."Europe's pharmaceutical giants are under pressure as the sector faces alooming loss of exclusivitiesRoch
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche (RHHBY) was upgraded by Morgan Stanley from "underweight" to "equal weight". They now have a $46.00 price target on the stock.MarketBeat
- Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME' Campaign [Yahoo! Finance]Yahoo! Finance
- Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ CampaignBusiness Wire
- Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call Transcript [Seeking Alpha]Seeking Alpha
- LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor [Yahoo! Finance]Yahoo! Finance